We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$957M
AUM Growth
+$1.08M
Cap. Flow
-$9.87M
Cap. Flow %
-1.03%
Top 10 Hldgs %
32.99%
Holding
140
New
9
Increased
34
Reduced
55
Closed
6

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$11.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$9.5M
3
ONC
BeOne Medicines Ltd
ONC
+$9.49M
4
INCY icon
Incyte
INCY
+$8.91M
5
CELG
Celgene Corp
CELG
+$8.11M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$20.7M
2
GILD icon
Gilead Sciences
GILD
+$16.8M
3
ABMD
Abiomed Inc
ABMD
+$10.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$8.6M
5
ABBV icon
AbbVie
ABBV
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Financials 0.41%
3 Industrials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENT
101
DELISTED
Intersect ENT, Inc
XENT
$1.25M 0.13%
38,430
-2,570
-6% -$77.1K
PODD icon
102
Insulet
PODD
$11.4B
$1.24M 0.13%
18,000
– –
CAH icon
103
Cardinal Health
CAH
$53.5B
$1.23M 0.13%
20,000
– –
CLVS
104
DELISTED
Clovis Oncology, Inc.
CLVS
$1.22M 0.13%
18,000
-500
-3% -$35K
PRTA icon
105
Prothena Corp
PRTA
$453M
$1.18M 0.12%
31,350
-6,050
-16% -$308K
ICPT
106
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.13M 0.12%
19,400
+10,900
+128% +$687K
RDUS
107
DELISTED
Radius Health, Inc.
RDUS
$1.07M 0.11%
33,800
-2,700
-7% -$84.7K
PFE icon
108
Pfizer
PFE
$143B
$1.06M 0.11%
30,777
– –
ACAD icon
109
Acadia Pharmaceuticals
ACAD
$4.38B
$1.05M 0.11%
35,050
-81,950
-70% -$2.62M
DVAX
110
DELISTED
Dynavax Technologies
DVAX
$1.03M 0.11%
55,000
-4,500
-8% -$90.3K
OMCL icon
111
Omnicell
OMCL
$2.09B
$970K 0.1%
+20,000
New +$1.01M
HMSY
112
DELISTED
HMS Holdings Corp.
HMSY
$907K 0.09%
53,500
– –
VAR
113
DELISTED
Varian Medical Systems, Inc.
VAR
$778K 0.08%
7,000
– –
GKOS icon
114
Glaukos
GKOS
$9.21B
$770K 0.08%
30,000
– –
NVRO
115
DELISTED
NEVRO CORP.
NVRO
$739K 0.08%
10,700
– –
CLLS
116
Cellectis
CLLS
$265M
$710K 0.07%
+24,350
New +$663K
COTV
117
DELISTED
Cotiviti Holdings, Inc.
COTV
$699K 0.07%
21,708
– –
GWPH
118
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$653K 0.07%
4,950
-1,050
-18% -$123K
CVS icon
119
CVS Health
CVS
$137B
$638K 0.07%
8,800
– –
INO icon
120
Inovio Pharmaceuticals
INO
$92.1M
$579K 0.06%
11,675
-325
-3% -$20.1K
BIVV
121
DELISTED
Bioverativ Inc. Common Stock
BIVV
$550K 0.06%
10,200
-12,550
-55% -$687K
QTNT
122
DELISTED
Quotient Limited Ordinary Shares
QTNT
$545K 0.06%
2,750
– –
ESPR
123
DELISTED
Esperion Therapeutics
ESPR
$514K 0.05%
7,800
-200
-3% -$10.8K
MLNT
124
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$507K 0.05%
+6,420
New +$475K
ENDP
125
DELISTED
Endo International plc
ENDP
$490K 0.05%
63,200
-51,800
-45% -$388K
2 3 4
5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2017 Portfolio in Review

As of Q4 2017, Bellevue Group held 140 positions worth $957M, up 0.11% from $956M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group's Q4 2017 filing shows 9 new, 34 increased, 55 reduced and 6 closed positions. Its largest new stake was Supernus Pharmaceuticals: 240,400 shares worth $9.58M. The largest sale was Amgen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Group's largest Q4 2017 buy was Supernus Pharmaceuticals: 240,400 shares worth $9.58M.
  • Bellevue Group added most to DexCom in Q4 2017, an estimated $11.5M increase.
  • Bellevue Group's biggest Q4 2017 reduction was Amgen, cutting an estimated $20.7M.
  • Bellevue Group fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, selling an estimated $8.6M.
  • Bellevue Group's ten largest holdings make up 33% of its $957M portfolio in Q4 2017.
  • Bellevue Group opened 9 new positions and closed 6 in Q4 2017.
  • Bellevue Group's portfolio value rose 0.11% quarter-over-quarter to $957M.

Based on Bellevue Group's 13F filing for Q4 2017, filed 14 Feb 2018.